NCT02066285View on ClinicalTrials.gov

Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2019

Study Completion Date

March 24, 2023

Conditions

Solitary Fibrous TumorExtraskeletal Myxoid Chondrosarcoma

Interventions

DRUG

Pazopanib

Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.

Trial Locations (7)

38320

H. Universitario de Canarias, Santa Cruz de Tenerife

41013

Hospital Universitario Virgen del Rocío, Seville

Unknown

H. Son Espases, Palma de Mallorca

Hospital de la Santa Creu i Sant Pau, Barcelona

Hospital La Paz, Madrid

Hospital Ramón y Cajal, Madrid

H. Miguel Servet, Zaragoza

All Listed Sponsors

lead

Grupo Espanol de Investigacion en Sarcomas

OTHER

NCT02066285 - Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma | Biotech Hunter | Biotech Hunter